Fig. 6: Inhibition of KLF5 overcomes oxaliplatin resistance in xenograft tumors. | Cell Death & Disease

Fig. 6: Inhibition of KLF5 overcomes oxaliplatin resistance in xenograft tumors.

From: KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response

Fig. 6

A, B Nude mice were injected s.c. with CRC cells. After tumor diameter reached approximately 5 mm, mice were treated with oxaliplatin alone or in combination with ML264 as indicated. Tumor volume at indicated time points was calculated and plotted (mean ± SD, n = 3 for each group, one-way ANOVA, **P < 0.01, NS not significant). C The combined use of ML264 can significantly inhibit tumor growth in xenograft tumors (mean ± SD, n = 3 for each group, one-way ANOVA, **P < 0.01, *** p < 0.001). D TUNEL and Ki-67 immunostaining were used to analyze the apoptosis level of xenograft tumors. Arrows indicate example cells with positive staining. ML264 significantly restored the oxaliplatin-induced tumor apoptosis (mean ± SD, n = 3 for each group, one-way ANOVA, **P < 0.01, *** p < 0.001). Scale, 200 μm. E Western blotting was used to analysis KLF5, Bcl-2 and cleaved caspase 3. The concentration of ML264 was 25 mg/kg, and the concentration of oxaliplatin was 5 mg/kg (mean ± SD, n = 3 for each group, one-way ANOVA, **P < 0.01, *** p < 0.001).

Back to article page